Trends and outcomes of thrombolytics in patients with STEMI
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242586Keywords:
STEMI, In-hospital mortality, ThrombolysisAbstract
Background: In ST-segment elevation myocardial infarction (STEMI) percutaneous coronary intervention (PCI) is the gold standard, but the time/resource constraints can necessitate alternative approaches. This study aimed to analyze outcomes and predictors of in-hospital mortality in STEMI patients undergoing thrombolysis.
Methods: A retrospective analysis of national inpatient sample data (2016-2020) included adult patients admitted with STEMI. Using ICD-10 procedural codes, patients undergoing thrombolysis or PCI were identified. Elixhauser’s comorbidity index identified comorbidities, and univariate and multivariate analyses adjusted for confounders. The primary outcome was mortality rates in STEMI patients undergoing thrombolysis versus PCI. Secondary outcomes were factors influencing mortality rates and major complications associated with thrombolysis.
Results: Out of 819,979 patients diagnosed with STEMI, 0.2% (2349 patient’s) received thrombolysis as their primary treatment upon admission. The mortality rate among patients undergoing thrombolysis was 12.34% versus 4.09% with PCI. Additionally, a higher proportion of patients undergoing thrombolysis required left ventricular assist device (LVAD) (4.8% versus 0.89% in the PCI group), and the incidence of cardiogenic shock was significantly elevated in this cohort (10.8% versus 6.68% in the PCI group). Factors influencing in-hospital mortality among patients undergoing thrombolysis included age (with a 3% increase in mortality observed with each year of age), LVAD placement (patients with LVADs had 3.6 times higher odds of mortality compared to those without, with aOR 3.69, p=0.029, 95% CI 1.14-11.89), and the use of mechanical ventilation, which independently predicted mortality outcomes.
Conclusions: Thrombolysis in STEMI patients is a vital alternative to PCI. It is associated with higher mortality and complications compared to PCI. Age, LVAD placement, and mechanical ventilation independently predict mortality. Identifying these factors can help us improve the outcomes of thrombolysis. Further prospective research is warranted to optimize outcomes in thrombolysis for STEMI.
References
Terkelsen CJ, Sørensen JT, Maeng M, Jensen LO, Tilsted HH, Trautner S, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA. 2010;304(7):763-71.
Stone GW, Brodie BR, Griffin JJ, Morice MC, Costantini C, St Goar FG, et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary angioplasty in myocardial infarction stent pilot trial investigators. J Am Coll Cardiol. 1998;31(1):23-30.
O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):485-510.
Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13-20.
Chandrashekhar Y, Alexander T, Mullasari A, Kumbhani DJ, Alam S, Alexanderson E, et al. Resource and infrastructure-appropriate management of ST-segment elevation myocardial infarction in low- and middle-income countries. Circulation. 2020;141(24):2004-25.
Vora AN, Holmes DN, Rokos I, Roe MT, Granger CB, French WJ, et al. Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry. JAMA Intern Med. 2015;175(2):207-15.
Puymirat E, Simon T, Cayla G, Cottin Y, Elbaz M, Coste P, et al. Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015. Circulation. 2017;136(20):1908-19.
Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360(26):2705-18.
Pandey M, Sivakumar M, Motes A, Aashish A, Modi D. Determining extracorporeal membrane oxygenation outcomes in obese patients with ARDS. J Med Health Stud. 2024;5(2):85-92.
GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study Lancet. 2017;390(10100):1260-344.
Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from ischemic heart disease. Circul Cardiovasc Qual Outcomes. 2019;12(6):e005375.
Elendu C, Amaechi DC, Elendu TC, Omeludike EK, Alakwe-Ojimba CE, Obidigbo B, et al. Comprehensive review of ST-segment elevation myocardial infarction: understanding pathophysiology, diagnostic strategies, and current treatment approaches. Medicine. 2023;102(43):e35687.
Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368(21):2004-13.
Ahmad M, Mehta P, Reddivari AKR, Mungee S. Percutaneous coronary intervention. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13-20.
Fernandez-Avilés F, Alonso JJ, Castro-Beiras A, Vázquez N, Blanco J, Alonso-Briales J, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet. 2004;364(9439):1045-53.
Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen E, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360(26):2705-18.
Al Shammeri O, Garcia L. Thrombolysis in the age of Primary Percutaneous Coronary Intervention: Mini-Review and Meta-analysis of Early PCI. Int J Health Sci. 2013;7(1):91-100.
Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol. 2003;92(7):824-6.
Gibson CM. Primary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting. Ann Intern Med. 1999;130(10):841-7.
Hilleman DE, Tsikouris JP, Seals AA, Marmur JD. Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007;27(11):1558-70.
Khera R, Krumholz HM. With great power comes great responsibility. Circul Cardiovasc Qual Outcomes. 2017;10(7).
